TD Asset Management Inc. Has $6.86 Million Stake in IDEXX Laboratories, Inc. (IDXX)

TD Asset Management Inc. decreased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,095 shares of the company’s stock after selling 1,704 shares during the period. TD Asset Management Inc. owned 0.05% of IDEXX Laboratories worth $6,856,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in IDXX. Koch Industries Inc. grew its holdings in shares of IDEXX Laboratories by 44,533.1% in the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after acquiring an additional 1,396,113 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of IDEXX Laboratories by 486.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock valued at $182,711,000 after acquiring an additional 938,888 shares in the last quarter. BlackRock Inc. grew its holdings in shares of IDEXX Laboratories by 10.5% in the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares in the last quarter. Old Mutual Global Investors UK Ltd. bought a new position in shares of IDEXX Laboratories in the 2nd quarter valued at about $83,723,000. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of IDEXX Laboratories by 42.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after acquiring an additional 392,790 shares in the last quarter. Institutional investors own 86.80% of the company’s stock.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $159.30 on Tuesday. IDEXX Laboratories, Inc. has a one year low of $113.71 and a one year high of $173.01. The stock has a market cap of $13,518.90, a PE ratio of 52.19, a P/E/G ratio of 2.34 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. During the same period last year, the business posted $0.62 EPS. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. equities analysts predict that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on IDXX shares. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Canaccord Genuity restated a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a report on Friday, October 6th. Finally, Bank of America upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $173.67.

In related news, Chairman Jonathan W. Ayers sold 54,000 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total value of $8,171,280.00. Following the completion of the sale, the chairman now directly owns 1,064,573 shares in the company, valued at approximately $161,091,186.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the completion of the sale, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at $163,678,098.75. The disclosure for this sale can be found here. Insiders sold a total of 110,000 shares of company stock valued at $16,686,200 over the last quarter. 2.77% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This article was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2017/12/05/td-asset-management-inc-has-6-86-million-stake-in-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply